🇺🇸

US SEC Filing Intelligence

· daily

US SEC Filings Daily Market Digest — May 01, 2026

Across 50 SEC filings for May 1, 2026, Q1 2026 earnings dominate with mixed sentiment in 70% of reports, reflecting resilient revenue growth averaging +10% YoY in financial services and asset management (e.g., Ares +25% management fees, Piper Sandler +33% revenues) offset by declines in industrials and homebuilding (-10-20% YoY in Wabash, Dream Finders). Capital allocation trends emphasize shareholder returns with 12 companies announcing buybacks (e.g., Align Tech $200M, Ryan Specialty $40M shares retired) and dividends (e.g., Ares $1.35/share, TPG $0.59/share), while M&A activity surges including UWM's revised $12 cash/2.33 share offer for Two Harbors and Esperion's $3.16/share buyout at 58% premium. Cash flow pressures persist with 15 companies reporting negative operating cash flow QoQ (e.g., Cinemark -$20.4M, SL Green -$17.6M), and margin compression in 8/15 manufacturing filings averaging -150 bps YoY amid cost inflation. Guidance largely maintained or raised (e.g., Newell flat to +2%, Estee Lauder high-single digit organic), signaling stabilization, but backlog builds in select areas like Wabash +$132M QoQ. Portfolio-level patterns show asset managers outperforming (AUM growth 18%+), real estate mixed with impairments, and 13F filings revealing tech-heavy institutional bets (e.g., Sawgrass $30B+ in Apple/NVIDIA). Implications favor defensive financials and buyback plays amid macro uncertainty, with near-term catalysts from May 1 calls.

15 high priority 35 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — May 01, 2026

Across 50 SEC filings from the USA S&P 500 Consumer Discretionary stream (broadly including adjacent financials, industrials, and REITs), Q1 2026 results reveal mixed performance with average revenue growth of ~11% YoY among 18 reporting firms (e.g., Cboe +29%, Cinemark +19%, Boston Scientific +12%), but 10/18 showed profitability declines averaging -35% YoY due to margin compression (-150 bps avg in 7 cases) and rising costs. Capital allocation remains shareholder-friendly, with buybacks totaling >$150M (Fulgent $40M, Cboe $73M incl. plans, CubeSmart $33M) and dividend increases (Federal Realty +3%, BNY Mellon steady 24% payout). Guidance changes are net positive: raises at Cboe (organic revenue to mid-teens), Federal Realty (FFO $7.46-$7.55), lowered expenses at Cboe/Smurfit offsets. M&A/refinancing activity boosts flexibility (Herbalife $45M annual savings, Burke & Herbert merger to 100 branches), while 12 13F filings highlight institutional conviction in consumer staples/tech proxies like Yum China ($555M BLS), Walmart ($64M FourPath). Cash flow trends weak (9/15 negative OCF), signaling near-term risks amid workforce cuts (Cboe -20%) and compliance issues (Greenidge Nasdaq). Portfolio-level: outperformance in exchanges/REITs vs. homebuilders/packaging underperformance, with catalysts from earnings calls and mergers.

21 high priority 29 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — May 01, 2026

Across the 50 filings in the USA S&P 500 Healthcare intelligence stream (with diverse sector exposure including financials, biotech, and industrials), Q1 2026 results reveal robust revenue growth averaging +40% YoY in reporting companies (e.g., Moderna +260%, SCI Engineered +133%, Cinemark +18.9%), but persistent negative operating cash flows in 8/15 Q1 filers (avg -$100M, e.g., Ryan -$167M, Cinemark -$20M) signal working capital strains despite margin improvements in 6 cases (e.g., Newell gross margin +100 bps to 33.1%). Capital allocation leans shareholder-friendly with buybacks totaling >$200M (Ryan $40M, Civeo $14M, Virtu $56M, Truist $1.1B shares) and steady dividends (BNY 24% payout, Alerus +5% to $0.21), while M&A activity (Boston Scientific Nalu $588M, Burke & Herbert merger) bolsters healthcare and financial footprints. Healthcare standouts like Boston Scientific (+11.6% sales YoY, +99% net income) and Moderna (+260% revenue) contrast mixed sentiment (12/20 mixed), with forward guidance raises in Newell (FY sales flat to +2%) and Civeo (FY rev $675-700M) providing near-term catalysts amid insider-agnostic filings. Portfolio-level trends show financials outperforming (avg net income +40% YoY in banks like Glacier +50.5%, Truist +17%) vs. consumer/industrials cash burn risks, implying rotation opportunities into growth healthcare names. Overall, bullish growth momentum tempers by liquidity concerns, favoring buyback-heavy firms with raised guidance.

24 high priority 26 medium 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — May 01, 2026

Across 10 DEF 14A proxy statements filed around May 1, 2026, a dominant theme is robust corporate governance with high director independence (>90% in cases like Dollar Tree), 100% independent committees, clawback policies, no option repricing, and hedging/pledging restrictions, signaling strong board oversight amid executive compensation scrutiny. Period-over-period trends reveal pockets of robust growth, notably Dick's Sporting Goods' net sales surging 28.1% YoY to $17.22B driven by Foot Locker acquisition, Pure Storage's (Everpure) FY26 revenue up 16% YoY to $3.7B with first $1B quarter and $1.9B subscription ARR, contrasting neutral sentiment elsewhere; Citi Trends shows modest audit fee growth of 4.1% YoY to $755K. All filings feature advisory votes on NEO compensation with boards recommending approval, highlighting pay-vs-performance disclosures spanning 2021-2026. Upcoming virtual AGMs clustered June 10-23, 2026, serve as key catalysts for shareholder sentiment on comp and governance. Portfolio-level patterns indicate retail/tech resilience via M&A and subscriptions, but outliers like AquaBounty's reverse split proposal and going concern risks flag distress in biotech/mining. Market implications favor governance leaders for lower volatility, with growth outliers offering upside amid neutral backdrops.

10 high priority 10 total filings
· daily

US IPO Pipeline SEC S-1 Filings — May 01, 2026

The IPO Pipeline stream features two neutral-sentiment filings on May 1, 2026: Lakewood-Amedex Biotherapeutics' S-1 registering 9,647,726 shares for resale by selling stockholders, signaling a key liquidity step for this Nevada-incorporated biotherapeutics firm, and Independent Bank Corp's (IBCP) S-4 advancing its merger with HCB Financial Corp under a March 18, 2026 agreement, with completion eyed for 2026. High materiality (8/10 for Lakewood, 9/10 for IBCP) underscores their importance, though no period-over-period financial trends, revenue growth, margin changes, or operational metrics are detailed in the filings, focusing attention on structural catalysts rather than quantitative performance. Overarching themes include biotech IPO progression and banking M&A via share registrations, with both filings incorporating exhibits and prior reports for transparency. Portfolio-level patterns show concentrated activity on a single day (2/2 filings May 1), neutral sentiment across the board, and forward-looking merger close in 2026 as a primary catalyst. Market implications point to potential new listings and consolidation plays, with watch for IPO roadshows and merger votes amid absent financial benchmarks.

2 high priority 2 total filings
· daily

Global High-Priority Regulatory Events — May 01, 2026

Across 50 filings from May 1, 2026, key themes include widespread distress in Indian infrastructure and real estate sectors with 6+ insolvencies, defaults totaling ₹300+ Cr (Jyoti ₹76 Cr, Ansal ₹61.82 Cr), and bankruptcies like Charles & Colvard, contrasted by robust US M&A and refinancing activity (McCormick $2B loan for Unilever acquisition, Herbalife $1.45B refinancing saving $45M annual interest). Q1 2026 10-Qs show mixed results: 12/18 reporting firms with revenue growth averaging +9% YoY (e.g., Boston Scientific +11.6%, SPX +17.5%), but net income volatility (7 firms with declines >20% YoY like Dream Finders -75.9%), margin compression in 8/12 (avg -100 bps), and cash flow pressures from acquisitions boosting goodwill (Verizon +34% QoQ). Capital allocation leans toward buybacks ($40M Ryan, $2.5B Verizon) and dividends, with 5 firms extending debt maturities for flexibility. Positive catalysts include takeovers (Esperion 58% premium) and equity raises (iQSTEL $50M facility), while risks cluster in bankruptcies and regulatory non-compliance. Portfolio implication: Favor US acquirers and refinancers over Indian distress names; monitor June catalysts for resolutions.

50 high priority 50 total filings
· daily

US Earnings Financial Results SEC Filings — May 01, 2026

Across 50 Q1 2026 10-Q filings, companies exhibited resilient revenue growth in approximately 70% of cases (avg +12% YoY where positive), led by tech (Teradyne +87%), financials (BNY Mellon +13%), and industrials (SPX +17.5%), but profitability was mixed with 40% reporting net income declines due to M&A integration costs, impairments, and one-offs like First Merchants' $30M mortgage loss. Robust capital allocation prevailed, with 35+ firms executing buybacks (e.g., Verizon $2.5B, Ryan $40M) and dividends (e.g., BNY $0.53/share), signaling management conviction amid asset expansion from acquisitions in 20+ companies (totaling billions, e.g., SPX $440M, Boston Sci $588M). Margin compression affected 25% of filers (avg -150bps, e.g., Smurfit -196bps gross), while operating cash flows improved YoY in 60% (e.g., Cboe doubled). Financials and tech outperformed consumer/industrials, implying bullish rotation to growth sectors; however, real estate showed impairment risks (SL Green $35M reserves). Portfolio implication: Favor acquirers with strong cash flow and returns, avoid margin squeezes; M&A wave supports consolidation plays but watch integration.

50 high priority 50 total filings
· daily

US SEC Trading Suspension Halt Orders — May 01, 2026

Across six 8-K filings in the USA Trading Suspensions stream, a dominant theme emerges of Nasdaq compliance challenges, with 5/6 companies facing deficiencies primarily in minimum bid price (4 cases) and market value of listed securities (1 case), alongside one audit committee issue; only Onfolio Holdings regained compliance, serving as a positive outlier. No period-over-period financial trends (YoY/QoQ revenue, margins) or insider trading activity reported in any filing, limiting quantitative portfolio comparisons, but aggregate sentiment is negative (5/6), with high materiality (avg 8.5/10) signaling acute delisting risks. Critical developments include Curis facing imminent suspension on May 6, 2026 unless appealed by May 4, while others have 180-day cure periods ending October 26-27, 2026; Greenidge has until April 15, 2027. Market implications point to heightened volatility, potential OTC delistings eroding liquidity and shareholder value for small-cap biotechs (Atara, Curis) and energy/tech firms (Greenidge, Rekor, CBAK). Portfolio-level pattern: 4/6 triggered by 30 consecutive business days below $1 bid price from mid-March to late April 2026, reflecting broad small-cap price pressure amid 2026 market dynamics. Onfolio's 10-day compliance from April 16-29, 2026 highlights potential for rapid turnarounds via price recovery.

6 high priority 6 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — May 01, 2026

Across 50 8-K filings dated around May 1, 2026, corporate distress signals are rampant in the US small/mid-cap space, with 12 companies (24%) facing Nasdaq delisting risks primarily from sub-$1 bid prices (e.g., Curis, Rekor, CBAK) or low MVLS (Atara), signaling liquidity crunches and potential trading suspensions by Oct 2026. High-cost, dilutive financings dominate (e.g., NextNRG 203% APR loan, iQSTEL 94% VWAP equity line, PDS $6M note), reflecting cash burn pressures absent explicit YoY declines but inferred from repeated bridge/ATM raises (10+ instances). Larger firms show resilience via favorable refinancings (Herbalife $45M annual interest savings post-$1.45B refi, McCormick $2B term loan for M&A) and equity raises (National Healthcare 44M+ shares). One outright Ch11 bankruptcy (Charles & Colvard asset sale June 22) and liquidation plan (Origin Materials, 59% workforce cut saving $14M/yr). No broad insider selling patterns, but equity grants (e.g., National Healthcare 995k shares to execs) indicate retention focus; capital allocation tilts to survival (debt extensions like Diameter -23% facility but +2yr maturity). Portfolio trend: margin-neutral sentiment (28 neutral, 12 positive, 10 mixed/negative), with Oct 2026 as key catalyst cliff for delistings amplifying volatility.

50 high priority 50 total filings
· daily

US Executive Officer Management Changes SEC — May 01, 2026

Across 44 filings in the USA Executive & Director Changes stream (40 new), a dominant theme is strong shareholder support at 2026 AGMs, with 12+ companies (e.g., Sonic Automotive 85-95% director approvals, Truist 89% quorum, TechnipFMC 98%+ proposals) signaling board stability and approval of comp/equity plans. CFO and key exec churn is evident in 12 cases (e.g., Worksport, Cisco CAO, KB Home CFO, Natural Alternatives CFO resignations), mostly neutral without disagreements, often with internal promotions or experienced replacements. Period-over-period trends show mixed financials: Perella Weinberg revenues -30% YoY to $148.9M with comp ratio +12pts to 82%; Universal Logistics revenues -4% YoY to $367.6M, swing to $(3.5M) net loss; BioRestorative exec comp +83% CEO YoY to $2.4M. Positive appointments (e.g., Carter’s new CEO Sharon Price John, Deere CFO Brent Norwood) and M&A integrations (Stock Yards adding branches/CEO) highlight growth strategies. Capital allocation remains shareholder-friendly with dividends (Perella $0.07, Universal $0.105). Portfolio implications: Monitor finance role turnover for small/mid-caps as potential early warning; bullish on industrials/autos with expert board adds.

44 high priority 44 total filings
· daily

US Corporate Board Director Changes SEC Filings — May 01, 2026

Across 44 SEC filings on USA Board Room Changes from May 1, 2026, the dominant theme is proactive executive and board enhancements, with 22 appointments/promotions of seasoned leaders (e.g., CEOs, CFOs, directors from high-profile firms) signaling strategic bolstering amid economic uncertainty, particularly in financials (9 filings) and industrials (8 filings). Period-over-period trends reveal mixed financial health: Perella Weinberg revenues -30% YoY to $148.9M with comp ratio +1200bps to 82%, Universal Logistics revenues -4% YoY to $367.6M swinging to $(3.5)M net loss from $6M profit, while capital returns remain resilient (e.g., Perella $63.8M returns, $0.07 dividend; Universal $0.105 dividend). Resignations (17 instances, all amicable without disagreements) cluster around CFOs/CLOs, but transitions are orderly with interim successors or searches launched. Annual meetings (14 filings) showed overwhelming approvals (>90% for directors/auditors in most), reflecting shareholder confidence. Forward-looking catalysts include leadership stabilizations driving growth (Carter’s reaffirmed FY26 guidance pre-May 6 earnings) and M&A integrations (Stock Yards adding branches). Portfolio implication: Bullish for firms adding oil/gas (Flowco), M&A talent (Perella), and internal promotions (Owens Corning, Deere); monitor CFO turnover for operational risks.

44 high priority 44 total filings
· daily

US Merger & Acquisition SEC Filings — May 01, 2026

The 15 filings reveal heightened M&A and takeover activity in US markets, with 8 completions or announcements including bank mergers (Burke & Herbert/LINKBANCORP), energy acquisitions (Diversified Energy $248M), IP deals (Lunai Bioworks $20M valuation), and SPAC mergers (GalaxyEdge/Rongcheng $350M pre-money), signaling robust deal flow despite SPAC extensions in 4 cases. SPAC maneuvers dominate with 1 IPO ($250M RRE Ventures), 3 deadline extensions (Live Oak to Jul 15 2026, Drugs Made In America/AltEnergy to 2027), and management shifts (Bleichroeder). Period trends show WisdomTree's standout AUM +5.6% QoQ to $152.6B and revenues +47.5% YoY, contrasting Crown Castle's FY2026 guidance for AFFO growth ~$65M midpoint despite site rentals -~$200M YoY. Capital allocation shines with Crown Castle's $1B buyback + $7B debt cut post-$8.5B divestitures, WisdomTree's $0.03 dividend, and Diversified's debt-funded expansion. Portfolio-level patterns indicate financial services consolidation (2/15 bank-related), energy/biotech/AI tuck-ins, and SPAC persistence amid Nasdaq pressures (Quetta deficiency). Implications favor pure-play refinancings and post-merger footprints, but flag SPAC dilution risks and compliance hurdles.

15 high priority 15 total filings
· daily

Federal Construction & Infrastructure Contracts — April 30, 2026

The single contract analyzed totals $328,507,039 in obligations, entirely civilian with 0/1 defense-related, dominated by Department of State infrastructure spending on embassy construction. Caddell Construction Co. (DE), LLC secured this full and open competition award for a new embassy compound in Praia, Cape Verde, providing a bullish signal with $80M estimated annual revenue over ~4.1 years through 2028-11-08. This represents a significant, fully obligated firm fixed price revenue stream for the Montgomery, AL-based firm in NAICS 236220 commercial building construction. Highest-conviction signal is bullish growth for Caddell in State Department projects. Key risk is high pricing risk under firm fixed price terms with $0 outlayed to date; watch outlay progress and performance through 2028.

1 total filings
· daily

DHS Homeland Security Contracts — April 30, 2026

DHS awarded $353,996,604 in civilian contracts (0/2 defense-related) to General Atomics Aeronautical Systems, Inc. ($272.6M) and Rapiscan Systems Inc. ($81.4M), both to U.S. Customs and Border Protection (CBP) for UAS operations/maintenance and non-intrusive inspection equipment repair. The dominant theme is CBP sustainment of border security technologies, with the highest-conviction bullish signal on Rapiscan Systems Inc./OSI Systems, Inc. ($81.4M obligation, $42.7M outlayed, up to $153M ceiling through 2027). General Atomics' larger award shows neutral stability but low outlay progress ($34.3M vs. $272.6M obligated). Key watch item: outlay acceleration on both contracts amid potential option exercises.

2 total filings
· daily

HHS & Healthcare Contracts Intelligence — April 30, 2026

HHS's BARDA awarded a single $150,780,000 cost-no-fee definitive contract to Trustees of Boston University for CARB-X Global Antibacterial Accelerator OTA R&D, comprising 100% civilian obligations with 0/1 defense-related. This 2022 award, running to May 31, 2029 (potentially 2032), has $75,505,831 outlayed and 107 subawards totaling $63,748,654, emphasizing subcontracting in NAICS 541714 biotechnology R&D. The dominant agency theme is BARDA's sustained commitment to health preparedness basic research (PSC AN41). Highest-conviction signal is low pricing risk on this full-and-open competition award to the nonprofit university. Key watch item is progress on the remaining ~$75M obligation and potential exercise of options to reach the $285,780,000 ceiling.

1 total filings
· daily

New Federal Contractors — April 30, 2026

These six new federal contracts total $1,188,107,721 in obligations, entirely civilian with 0/6 defense-related, highlighting sustained non-DOD spending across State, DHS, NSF, and HHS agencies. Dominant themes include embassy construction (State), border security sustainment (DHS), IT services (NSF), and health preparedness R&D/waste management (HHS), with average signal strength of 5.7/10. Highest-conviction bullish signals stem from Caddell Construction's $328.5M State embassy build and Booz Allen Hamilton's $254.5M NSF IT delivery order, both via full/open competition signaling competitive strength. Key risk is high fixed-price execution exposure on Caddell ($328.5M), Inmar RX ($100.3M), and Rapiscan ($81.4M) contracts, alongside variable outlay progress (e.g., $0 on Caddell). Watch multi-year option exercises and outlay ramps through 2027-2029 for revenue visibility.

6 total filings
· daily

Significant Contract Modifications ($10M+) — April 30, 2026

These six significant civilian contract modifications total $1,188,107,721 in obligations, with 0/6 defense-related awards spanning State, DHS (two), NSF, and HHS (two) agencies. Dominant themes center on long-term construction (Caddell $328.5M State embassy), IT services (Booz Allen $254.5M NSF), and sustainment services in health R&D/preparedness (HHS) and border security (DHS). Highest-conviction bullish signals emerge from Caddell Construction's fully obligated $328.5M firm-fixed-price embassy project and Booz Allen Hamilton's $254.5M IT order with $179.6M outlaid. Key risk is high pricing/execution exposure on firm-fixed-price awards like Caddell ($328.5M, $0 outlaid), Inmar RX ($100.3M), and Rapiscan ($81.4M).

6 total filings
· daily

Contract Deobligations Alert — April 30, 2026

This Contract Deobligations Alert synthesizes six civilian agency contracts totaling $1,188,107,721 in obligations, with 0/6 defense-related, highlighting sustained federal spending in construction, IT services, UAS maintenance, health R&D, and waste disposal despite the one-day reporting period in April 2026. Dominant themes center on Department of State infrastructure (Caddell at $328.5M), DHS support services ($354M combined for General Atomics and Rapiscan/OSI Systems), and HHS R&D/waste management ($251M for Boston University and Inmar RX). Highest-conviction bullish signals include Caddell Construction's fully obligated $328.5M embassy project and Booz Allen Hamilton's $254.5M NSF IT delivery order with $179.6M outlayed. Neutral signals dominate lower-materiality awards, but firm fixed-price execution risks on Caddell ($328.5M), Inmar RX ($100.3M), and Rapiscan ($81.4M) warrant monitoring alongside outlay progress on low-spend contracts like Caddell's $0 outlay.

6 total filings
· daily

Contract Option Exercises — April 30, 2026

This digest covers $1,188,107,721 in contract option exercises across 6 civilian awards (0 defense-related) from April 30, 2026 to April 30, 2026, dominated by Department of State, DHS, HHS, and NSF spending in construction, IT services, UAS maintenance, health R&D, waste disposal, and inspection equipment repair. Highest-conviction bullish signals emerge from Caddell Construction's $328.5M State embassy build and Booz Allen Hamilton's $254.5M NSF IT delivery order, both fully obligated via full and open competition with multi-year visibility to 2028 and 2025. Rapiscan's $81.4M DHS contract adds border security tailwinds for OSI Systems. Key risk: High firm-fixed-price execution risks on Caddell ($328.5M), Inmar ($100.3M), and Rapiscan ($81.4M) amid low-to-moderate outlays; watch option exercises and outlay progress across all.

6 total filings
· daily

Federal IT & Cybersecurity Contracts — April 30, 2026

The single contract analyzed totals $254,534,977 in obligations, entirely civilian with zero defense-related awards from the National Science Foundation (NSF). Booz Allen Hamilton Inc secured this major IT services delivery order under full and open competition, signaling strong positioning in civilian agency IT with $179.6M already outlayed and multi-year visibility through January 2025. The highest-conviction bullish signal is Booz Allen's reliable revenue stream from this NSF award, estimated at ~$46M annually. A key watch item is progress toward full $254.5M obligation and option exercises for the additional $2.45M ceiling, amid medium pricing risk.

1 total filings